Table 2.
Clinical outcomes
| Before treatment | After treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcome measures | Max score | N | Mean | SD | Median | Mean | SD | Median | Mean difference (99.5% CI) |
SD | Cohen’s d | t | df | Z |
| CORE | 4 | 32 | 1.72 | 0.64 | 0.78 | 0.53 | 0.94 (0.57 to 1.30) | 0.68 | 1.37 | 7.75** | 31 | |||
| CORE(−risk) | 4 | 32 | 1.99 | 0.72 | 0.92 | 0.61 | 1.07 (0.65 to 1.48) | 0.78 | 1.37 | 7.74** | 31 | |||
| Well-being | 4 | 32 | 2.16 | 0.93 | 0.99 | 0.80 | 1.17 (0.62 to 1.71) | 1.02 | 1.15 | 6.49** | 31 | |||
| Problems | 4 | 32 | 2.24 | 0.73 | 1.04 | 0.70 | 1.20 (0.74 to 1.66) | 0.86 | 1.40 | 7.90** | 31 | |||
| Functioning | 4 | 32 | 1.68 | 0.78 | 0.78 | 0.53 | 0.89 (0.50 to 1.29) | 0.73 | 1.22 | 6.90** | 31 | |||
| Risk | 4 | 32 | / | / | 0.25 | / | / | 0.00 | / | / | −1.06 a (−1.58 to −0.53) | / | / | −3.75** a |
| −1.11 b (−1.64 to −0.58) | −3.89** b | |||||||||||||
| PHQ-9 | 27 | 35 | 13.20 | 6.91 | 5.29 | 4.57 | 7.91 (4.95 to 10.87) | 5.83 | 1.36 | 8.03** | 34 | |||
| GAD-7 | 21 | 35 | / | / | 10.00 | / | / | 4.00 | / | / | −1.49 a (−2.01 to −0.95) | / | / | −4.77** a |
| −1.33 b (−1.85 to −0.81) | −4.63** b | |||||||||||||
| WSAS | 40 | 29 | 19.93 | 9.25 | 10.34 | 7.37 | 9.59 (4.55 to 14.62) | 8.90 | 1.08 | 5.80** | 28 | |||
aCohen’s d and Cohen’s d 95% CI (in brackets) of Sign test
bCohen’s d and Cohen’s d 95% CI (in brackets) of Wilcoxon Signed Rank test
**p < 0.001